


下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMerimepodibCat. No.: HY-13986CAS No.: 198821-22-6Synonyms: VI-21497; VX-497; MMP分式: CHNO分量: 452.46作靶點(diǎn): HBV; HCV作通路: Anti-infection儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 31 mg/mL (6
2、8.51 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.2101 mL 11.0507 mL 22.1014 mL5 mM 0.4420 mL 2.2101 mL 4.4203 mL10 mM 0.2210 mL 1.1051 mL 2.2101 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Merimepodib競(jìng)爭(zhēng)型,有服活性的肌苷磷酸脫氫酶 (IMPDH
3、) 抑制劑,具有譜抗病毒活性。體外研究VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. The antiproliferative effect of VX-497in cells is reversed within 48 h of its removal 1. VX-497 has intermediate antiviral activity against a secondgroup of viruses, which includes HSV-1, parainfluenza-3 virus
4、, BVDV, VEEV, and dengue virus, with IC50s1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEranging from 6 to 19 M. VX-497 is 100-fold more potent, with an IC50 of 380 nM and a corresponding CC50of 5.2 M, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG5 cells is reversedthreef
5、old by the addition of guanosine 2.體內(nèi)研究 Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, withan ED50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective astwice-daily dosing in this model of immune activa
6、tion 1. GVHD developed in the vehicle-treated allograftedF1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-foldincrease in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice.Serum IFN-gamma levels are in
7、creased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals 3.PROTOCOLCell Assay 2 The murine fibroblast L929 cell line is cultured in Eagle minimal essential medium supplemented with 10%fetal bovine serum, nonessential amino acids, 50 U of penicillin per mL, 50
8、 g of streptomycin per mL, and 2mM l-glutamine. EMCV is infected at 500 PFU/107 L929 cells. Cells are left untreated or are treated withdifferent concentrations of murine IFN- alone, VX-497 alone, or combinations thereof.MCE has not independently confirmed the accuracy of these methods. They are for
9、 reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Cell Mol Immunol. 2019 Aug. Antiviral Res. 2018 Jan;149:34-40.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Jain J, et al. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.2. Markland W, et
10、al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin anddemonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000 Apr;44(4):859-66.3. Decker CJ, et al. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. DrugsExp Clin Res. 2001;27(3):89-95.McePdfHeightCaution: Product has not been fully
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 廣東省深圳市寶安區(qū)文匯學(xué)校2020-2021學(xué)年八年級(jí)下學(xué)期3月月考數(shù)學(xué)試題
- 生物-山東省淄博市濱州市2024-2025學(xué)年度2025屆高三模擬考試(淄博濱州一模)試題和答案
- 2020-2021深圳南聯(lián)學(xué)校初中部小學(xué)三年級(jí)數(shù)學(xué)上期中第一次模擬試題含答案
- 火災(zāi)逃生知識(shí)培訓(xùn)課件
- 2025年中考道德與法治一輪復(fù)習(xí):九年級(jí)下冊(cè)必背考點(diǎn)提綱
- 電梯消防施工方案
- 2025年高考地理一輪復(fù)習(xí):人教版(2019)高中地理必修第二冊(cè)知識(shí)點(diǎn)背誦提綱
- 農(nóng)村超級(jí)地基施工方案
- 鋼制門窗防水施工方案
- 2025年天津市河?xùn)|區(qū)高三一模高考數(shù)學(xué)模擬試卷(含答案)
- 2024年黑龍江公務(wù)員《行政職業(yè)能力測(cè)驗(yàn)》試題真題及答案
- 2025年鄂爾多斯職業(yè)學(xué)院?jiǎn)握新殬I(yè)適應(yīng)性測(cè)試題庫(kù)必考題
- 項(xiàng)目立項(xiàng)申請(qǐng)書與立項(xiàng)調(diào)研報(bào)告
- 2025年企業(yè)與個(gè)體工商戶長(zhǎng)期供銷合同模板
- 2025年全民國(guó)家安全教育日主題教育課件
- 北京市石景山區(qū)2024-2025學(xué)年高三上學(xué)期期末英語試題【含答案解析】
- 聲學(xué)基礎(chǔ)課后題答案
- 腫瘤專業(yè)十種常見疾病質(zhì)量控制指標(biāo)全年統(tǒng)計(jì)表
- 體育與健康-羽毛球運(yùn)動(dòng)
- 2025年南京信息職業(yè)技術(shù)學(xué)院高職單招語文2018-2024歷年參考題庫(kù)頻考點(diǎn)含答案解析
- 12J201平屋面建筑構(gòu)造圖集(完整版)
評(píng)論
0/150
提交評(píng)論